In the Specification

Please amend the specification as follows:

At the bottom of page 4 to the top of page 5, please amend the specification as follows:

A p53 binding region according to the invention may be present as such or in combination with any other DNA. For example, a p53 binding region according to the invention may be present in a vector, optionally in combination with a reporter DNA, e.g. luciferase DNA. Preferred combinations are the DNA constructs CD95(Ps)-LUC, CD95(P)-LUC, CD95(I+SV)-LUC, CD95(Ps+I)-LUC, p1139, p1140, p1141, p1142, p1140 IMI, p1140 IMII, p1140 IMIII, p1140 IMIV, p1141 IMIJI, p1141 1p53, p1141 2p53, p1141 3p53, p1141 ΔBgI, p1141 ΔSpe, p1141 ΔMph, p1142 TAG, p1142 IMIII, p1142 Δ Bg1, p1142 Δ Spe and p1142 Δ Mph, in which a p53 binding invention is present region according to the expression vectors pGL3-Basic and/or pTATA-LUC. As to the DNA CD95(P)-LUC, CD95(I+SV)-LUC, CD95(Ps)-LUC, constructs CD95(Ps+1)-LUC, reference is made to Example 3 and figure 6. The DNA constructs p1139, p1140, p1141, p1142, p1140 IMI, p1140 IMII, p1140 IMIII, p1140 IMIV, p1141 IMIIJ, p1141 1p53, p1141 2p53, p1141 3p53, p1141 ΔBgl, p1141 ΔSpe, p1141 ΔMph, p1142 TAG, p1142 IMJI, p1142 Δ Bgl, p1142 Δ Spe, and p1142 Δ Mph contain the sequences indicated in figures 7 (SEQ ID NO. 2), 8 (SEQ ID 9 (SEQ ID NO. 4), or 10 (SEQ ID NO. 1), i.e. p53 binding regions or variations thereof (cf. figures 11 (SEQ ID NOs. 6, 7, 8 and 9), 12 (SEQ ID NOs. 11, 23, 25 17 and 19) and 13 (SEQ ID NOs. 25, 27, 29, and 31)). The DNA constructs p1139, p1140, p1141 and p1142 are preferred and were deposited with Zellen fur Mikroarganismen und Sammiung (Deutsche DSMZ [German-type collection of microorganisms and cells])

September 24, 1999, i.e. pl139 under DSM 3075, pl140 under DSM 13062, pl141 under DSN 13063 and pl142 under DSM 13064.

At pages 5, 6 and 7, please amend the Figure paragraphs as follows:

Figure 1 shows the expression of the CD95 receptor in tumor cells after treating them with chemotherapeutic agents. Clinically relevant concentrations of the chemotherapeutic agents are marked with an asterisk. The tumor cells express p53, no p53 (-/-p53) or p53 disturbed as regards the binding to an inventive p53 binding region of a CD95 receptor DNA (mt p53).

Figure 2 shows the response of tumor cells treated with chemotherapeutic agents to the induction of apoptosis by CD95 receptor stimulation.

Figure 3 shows the expression of the CD95 receptor in tumor cells treated with a chemotherapeutic agent, the tumor cells expressing p53 only after transfection with an expression plasmid coding for p53.

Figure 4 shows a p53 binding region according to the invention $(p53 \ BE)$ within intron 1 of a CD95 receptor DNA.

Figure 5 shows a p53 binding region according to the invention (p53 BE) within the promoter of a CD95 receptor DNA comprising 9 exons. The promoter has three p53 binding regions.

Figure 6 shows the expression of a luciferase DNA after the binding of p53 to a p53 binding region according to the

invention within an expression plasmid containing the luciferase DNA.

Figure 7 shows the sequence of a p53 binding region according to the invention (SEQ ID NO. 2), the sequence comprising the nucleotides 1--720 of intron I of the CD95 receptor DNA. The p53-BE sequence is marked in boldface.

Figure 8 shows the sequence of a p53 binding region according to the invention (SEQ ID NO. 3), the sequence comprising nucleotides 448 - 2154 of the promoter, exon I and the nucleotides 2223 - 2827 (correspond to nucleotides 116 - 720 of the sequence of figure 7) of intron I of the CD95 receptor DNA. The p53-BE sequences are marked in boldface.

Figure 9 shows the sequence of a p53 binding region according to the invention (SEQ ID NO. 4), the sequence comprising nucleotides 1-2154 of the promoter, exon I and nucleotides 2223-2827 of intron I of the CD95 receptor DNA. The p53-BE sequences are marked in boldface.

Figure 10 shows the sequence of a p53 binding region according to the invention (SEQ ID NO. 1), the sequence comprising nucleotides 1-2154 of the promoter, exon I together with its 3' region and nucleotides 2223-2820 of intron I together with its 5'-region of the CD95 receptor DNA. The p53-BE sequences are marked in boldface.

Figure 11 shows variations in the p53 binding region of figure 8 (SEQ ID NOs. 6, 7, 8, and 9), the variations being point mutations in intron I of the CD95 receptor DNA.

Figure 12 shows variations in the p53 binding region of figure 9 (SEQ ID NOs. 11, 13, 15, 17 and 19), the variations being point mutations in intron I and in the promoter as well as deletions in the promoter of the CD95 receptor DNA.

Figure 13 shows variations in the p53 binding region of figure 10 (SEQ ID NOs. 25, 27, 29 and 31), the variations being point mutations in intron I and in exon I as well as deletions in the promoter of the CD95 receptor DNA.

Figure 14 shows a physical map of p53 binding regions according to the invention, (a) being the binding region of figure 7 (SEQ ID NO. 2), (b) being that of figure 8 (SEQ ID NO. 3), (c) being that of figure 9 (SEQ ID NO. 4), and (d) being that of figure 10 (SEQ ID NO. 1).